| HOME >> BIOLOGY >> TECHNOLOGY |
Toronto Stock Exchange Symbol: MS
EDMONTON, May 28 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Randy Stroud, Vice President Regulatory Affairs, will present at the Canadian Society for Pharmaceutical Sciences 12th Annual Meeting & Symposium.
TITLE: "Dirucotide: A Potential Therapy for Multiple Sclerosis"
WHEN: Thursday June 4th at 2:00 pm (Eastern Time)
WHERE: Hyatt Regency Hotel, Toronto, Ontario, Canada
About the Canadian Society for Pharmaceutical Sciences (CSPS)
-------------------------------------------------------------
CSPS is the premier organization for bringing together Pharmaceutical Scientists across Canada. The 12th Annual Meeting & Symposium focus is "Drug Development to Regulatory Approval". For further information, please visit: http://www.cspscanada.org/symposium2009.aspx.
About BioMS Medical Corp.
-------------------------
BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for Secondary Progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide in exchange for an upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.
This press release may contain forward-l
'/>"/>
| SOURCE BioMS Medical Corp. Copyright©2009 PR Newswire. All rights reserved |